Prostate cancer and adiponectin.

Area of Science:

• Oncology
• Endocrinology
• Urology

Background:

• Prostate cancer (PCa) is a growing public health concern, especially in aging populations.
• Obesity and insulin resistance are associated with increased PCa risk.
• Adiponectin, a hormone involved in metabolic regulation, is a potential factor linking obesity and PCa.

Purpose of the Study:

• To investigate the relationship between plasma adiponectin levels and prostate cancer.
• To determine if adiponectin levels correlate with PCa cellular differentiation, grade, or disease stage.

Main Methods:

• Plasma adiponectin levels were measured in 30 PCa patients, 41 benign prostatic obstruction patients, and 36 healthy controls.
• PCa patients were categorized by disease spread (organ-confined vs. advanced) and Gleason grade (low, intermediate, high).
• Demographic factors like age and body mass index were similar across groups.

Main Results:

• Plasma adiponectin levels were significantly lower in PCa patients compared to controls and benign prostatic obstruction groups.
• Advanced PCa and high-grade PCa showed significantly lower adiponectin levels than organ-confined or lower-grade PCa.
• Adiponectin levels negatively correlated with prostate-specific antigen (PSA) and Gleason scores.

Conclusions:

• Plasma adiponectin levels are reduced in PCa patients and correlate negatively with disease severity and histologic grade.
• These findings suggest a potential role for adiponectin in prostate cancer progression.
• Further prospective research is needed to confirm a causal relationship between adiponectin and PCa.